Ulcerative colitis<unk>  has been investigated in several studies in adult patients.date=June 2020}} Patients with moderate to severe active disease in whom conventional therapy or TNF-alpha antagonists were ineffective or could not be tolerated received either<unk>  or placebo. The main measure of effectiveness was the proportion of patients whose symptoms improved after six weeks of treatment.<unk>  was shown to be more effective than placebo: 47% (106 out of 225) of patients who received<unk>  showed an improvement in symptoms, compared with 26% (38 out of 149) of patients who received placebo. The study also showed that<unk>  maintained the effect up to 52 weeks more effectively than placebo. Moreover,<unk>  treatment was shown to achieve higher percentage of clinical remissions (31.3% vs. 22.5%) in patients with ulcerative colitis in comparison to adalimumab treatment. Crohn's disease In one main study in adult patients with moderate to severe active Crohn's disease in whom conventional therapy or TNF-alpha antagonists were ineffective or could not be tolerated,<unk>  was shown to be more effective than placebo: 15% (32 out of 220) of patients receiving<unk>  showed improved symptoms after 6 weeks of treatment, compared with 7% (10 out of 148) of patients on placebo. The maintenance of the effect up to 52 weeks was more effective with<unk>  than with placebo.
Vedolizumab
Mepolizumab
Nemolizumab
Certolizumab pegol
Belatacept
Natalizumab
Infliximab
Abatacept